Protocol First secures Leukemia and Lymphoma Society funding
The clinical trial technology company received a funding commitment from the organization, intended to fuel ongoing investment, innovation and growth.
The clinical trial technology company received a funding commitment from the organization, intended to fuel ongoing investment, innovation and growth.
The two firms will pool their knowledge and resources on product delivery and administrative services for decentralized clinical trials.
The British CDMO will manufacture the API for the potential COVID-19 treatment, and partner Accord Healthcare will manufacture the finished product.
Moderna’s CEO comments on positive early results by highlighting the importance of its own manufacturing capabilities.